ACS CAN Comments on coverage of Next-Generation Sequencing (NGS) panels

January 17, 2018

ACS CAN supports the coverage of FDA-approved NGS panels, and also supports the coverage of panels used as part of NCI clinical trials.  CMS is encouraged to reconsider limitations on patient eligibility and is urged to create clear and achievable requirments for evidence development.